SITC 2021 | Areas of unmet need for patients with melanoma

Allison Betof Warner, MD, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, talks on key areas of melanoma that require more treatment options, including PD-1 refractory disease. Additionally, with brain metastasis being one of the predominant drivers of mortality in patients with melanoma, Dr. Betof emphasizes the need for research into treatment options for this subset of patients, as well as for NRAS mutated disease. The CheckMate204 (NCT02320058) trial is outlined, which explored the safety and efficacy of nivolumab plus ipilimumab, followed by nivolumab monotherapy in patients with melanoma that has spread to the brain. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.